V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Bausch & Lomb Executive Compensation (FY25)

BLCO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Brenton Saunders
Latest say-on-pay support
=
May 20, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Bausch & Lomb brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 20, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Bausch & Lomb brief$1,500Get the executive brief
Velarion Member, one year
412 figures on this page: 408 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Brenton Saunders: $23,860,756 → $32,194,326 (34.9% higher)
CEO pay ratio: 898:1 → 632:1 (29.6% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bausch & Lomb's chief executive and what were they paid?
Total compensation for Brenton Saunders, Chairman of the Board and Chief Executive Officer, came to $32,194,326 in fiscal 2025. Compared with the $23,860,756 reported for fiscal 2024, Saunders' total was 34.9% higher.
What was Bausch & Lomb's say-on-pay result?
Shareholders recorded 99.8% support for the say-on-pay proposal at the meeting held May 20, 2026 for fiscal 2025.
Which companies are in Bausch & Lomb's peer group?
The disclosed peer group includes Agilent Technologies, Inc., Alcon Inc., Align Technology, Inc., Dentsply Sirona Inc. and DexCom, Inc., among others.
What is Bausch & Lomb's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 632:1, against median employee compensation of $50,904.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Papa
Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Sam Eldessouky
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Christina Ackermann
Executive Vice President, General Counsel and Head of Government Affairs
◇—◇◇◇—◇◇
Joseph Gordon
President, Global Consumer, Surgical and Vision Care
◇—◇◇◇—◇◇
Yehia Hashad
Executive Vice President of Research & Development and Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brenton Saunders
President and Chief Executive Officer
◇◇◇◇◇—◇◇
Joseph Papa
Former Chief Executive Officer
Departed during or after this year
◇—————◇◇
Christina Ackermann
Former Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals
Departed during or after this year
◇◇◇◇◇—◇◇
Joseph Gordon
Former President, Global Consumer, Surgical and Vision Care
Departed during or after this year
◇◇◇◇◇—◇◇
A. Robert Bailey
Executive Vice President & Chief Legal Officer
◇◇◇◇◇—◇◇
Sam Eldessouky
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Yehia Hashad
Executive Vice President of Research & Development and Chief Medical Officer
◇—◇◇◇—◇◇
Andrew Stewart
President, Global Pharmaceuticals and International Consumer
◇◇◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brenton Saunders
Chairman of the Board and Chief Executive Officer
◇—◇◇◇—◇◇
Sam Eldessouky
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
A. Robert Bailey
Executive Vice President and Chief Legal Officer
◇—◇◇◇—◇◇
Yehia Hashad
Executive Vice President of Research & Development and Chief Medical Officer
◇—◇◇◇—◇◇
Andrew Stewart
President, Global Pharmaceuticals and International Consumer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brenton Saunders
Chairman of the Board and Chief Executive Officer
◇—◇◇◇—◇◇
A. Robert Bailey
Executive Vice President and Chief Legal Officer
◇—◇◇◇—◇◇
Yehia Hashad
Executive Vice President of Research & Development and Chief Medical Officer
◇—◇◇◇—◇◇
Andrew Stewart
President, Global Pharmaceuticals and International Consumer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
A. Robert D. BaileyPSU◇◇◇—◇—◇
A. Robert D. BaileyPSU◇◇◇—◇—◇
A. Robert D. BaileyRSU◇——◇——◇
A. Robert D. BaileyOPTION◇——◇—◇◇
Andrew J. StewartPSU◇◇◇—◇—◇
Andrew J. StewartRSU◇——◇——◇
Andrew J. StewartOPTION◇——◇—◇◇
Andrew J. StewartPSU◇◇◇—◇—◇
Brenton L. SaundersRSU◇——◇——◇
Brenton L. SaundersPSU◇◇◇—◇—◇
Brenton L. SaundersOPTION◇——◇—◇◇
Brenton L. SaundersPSU◇—◇—◇—◇
Brenton L. SaundersRSU◇——◇——◇
Brenton L. SaundersPSU◇◇◇—◇—◇
Sam A. EldessoukyRSU◇——◇——◇
Sam A. EldessoukyPSU◇◇◇—◇—◇
Sam A. EldessoukyOPTION◇——◇—◇◇
Sam A. EldessoukyPSU◇◇◇◇◇—◇
Yehia HashadPSU◇◇◇—◇—◇
Yehia HashadOPTION◇——◇—◇◇
Yehia HashadRSU◇——◇——◇
Yehia HashadPSU◇◇◇—◇—◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
A. Robert BaileyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/28/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/26/2035
Option◇—◇5/4/2033
Andrew StewartRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/28/2034
Option◇—◇2/26/2035
Yehia HashadRSU◇◇——
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/28/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇5/5/2032
Option◇—◇2/26/2035
Sam EldessoukyRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/26/2035
RSU◇◇——
RSU◇◇——
Option◇—◇5/5/2032
Option◇—◇2/28/2034
Brenton SaundersRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/28/2034
RSU◇◇——
RSU◇◇——
Option◇—◇2/23/2033
Option◇—◇2/26/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas W. Ross, Sr
Lead independent director
◇◇————◇
Sarah B. Kavanagh
◇◇————◇
Andrew C. von Eschenbach, M.D
◇◇————◇
Karen L. Ling
◇◇————◇
Nathalie Bernier
◇◇————◇
Russel C. Robertson
◇◇————◇
Gary Hu
◇◇————◇
John A. Paulson
◇◇————◇
Brett Icahn
◇◇————◇
Brenton L. Saunders, Eduardo Alfonso, M.D and Steven H. Collis served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Alcon Inc. ALC
  • Align Technology, Inc. ALGN
  • Dentsply Sirona Inc. XRAY
  • DexCom, Inc. DXCM
  • Edwards Lifesciences Corporation EW
  • Hologic, Inc. HOLX
  • Jazz Pharmaceuticals plc JAZZ
  • Organon & Co. OGN
  • Perrigo Company plc PRGO
  • ResMed Inc. RMD
  • Teleflex Incorporated TFX
  • The Cooper Companies, Inc. COO
  • Viatris VTRS
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024May 21, 2025=◇◇◇
2023May 29, 2024=◇◇◇
2022April 24, 2023=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Brenton Saunders (Chairman of the Board and Chief Executive Officer), FY2025 total compensation $32,194,326 (base salary $1,600,000) [exec_comp, SEC accession 0001140361-26-014234, filed 2026-04-10]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Bausch & Lomb files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bausch & Lomb disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bausch & Lomb sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Bausch & Lomb's disclosed peer group is defensible, who names Bausch & Lomb back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
412 figures on this page: 408 cited to the filing that reported them, 4 calculated from figures it prints.
408 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001193125-26-232712
  2. 0001140361-26-014234
    2025 B+L Director Compensation Table · 2025 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards · and 2 more sections
  3. 0001193125-25-124034
    Proposal No. 2: Advisory Vote on Executive Compensation.
  4. 0001140361-25-013244
    2024 Summary Compensation Table
  5. 0001193125-24-149259
  6. 0001308179-24-000628
    2023 Summary Compensation Table · Summary Compensation Table
  7. 0001193125-23-117046
  8. 0001308179-23-000138
    2022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bausch & Lomb executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BLCO (accessed 2026).
Short form: data: Velarion

The Bausch & Lomb brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bausch & Lomb and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Bausch & Lomb discloses

The companies named in BLCO's own disclosed peer group.

Agilent Technologies, Inc.Align Technology, Inc.Dentsply Sirona Inc.DexCom, Inc.Edwards Lifesciences CorporationHologic, Inc.Jazz Pharmaceuticals plcOrganon & Co.Perrigo Company plcResMed Inc.Teleflex IncorporatedThe Cooper Companies, Inc.ViatrisZimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy